We are delighted to announce that the University of Cambridge Enterprise Fund IV, managed by Parkwalk, has invested in PsyOmics, a spin-out from the Department of Chemical Engineering and Biotechnology.

The company aims to utilise blood-based diagnostics to increase the speed of diagnosis and to reduce misdiagnosis for mental health patients.

Mental illness accounts for over 15% of the disease burden in developed countries and in England alone, mental illness costs over £51.6bn per annum.